CoChat

Effect of Continuing and Discontinuing Medications on Quality of Life After Symptomatic Remission in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis

Open access
Tsujii, Noa, Okada, Takashi, Usami, Masahide, Kuwabara, Hidenori, Fujita, Junichi, Negoro, Hideki, Kawamura, Michiyo, Iida, Junzo, Saito, Takuya · 2020 · The Journal of Clinical Psychiatry

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: This study aimed to compare the effect of continuing and discontinuing medications on quality of life of patients with attention-deficit/hyperactivity disorder (ADHD). DATA SOURCES: PubMed, Cochrane Library, and Embase databases were searched using generic terms for ADHD, discontinuing, continuing, pharmacotherapy, and randomized controlled trials without date or language restrictions. STUDY SELECTION: Of the 3,672 screened studies, 9 met the predefined inclusion criteria on patients with ADHD; 5 of these 9 studies reporting on 1,463 patients (children and adolescents, n = 894; adults, n = 569) measured quality of life and were included in this meta-analysis. Only randomized, double-blind, placebo-controlled withdrawal trials of ADHD medications were included. DATA EXTRACTION: Data were independently extracted according to the Cochrane Handbook for Systematic Reviews of Interventions. Analyses were based on random-effects models. RESULTS: Compared with continuing medications, discontinuing them significantly worsened quality of life score in patients with ADHD (standardized mean difference [SMD] = 0.19; 95% CI, 0.08 to 0.30]). Moreover, discontinuing medications worsened this score in children and adolescents with ADHD (SMD = 0.21; 95% CI, 0.06 to 0.36) but not in adults with ADHD (SMD = 0.02; 95% CI, -0.46 to 0.50). CONCLUSIONS: Discontinuing medications was associated with a small but statistically significant decrease in quality of life among children and adolescents with ADHD but not in adults with ADHD. Quality of life can be applied in pharmacologic interventions regarding continuing and discontinuing medication because this concept is related to individuals' appraisal of their situation. Quality of life is an important factor for planning individualized ADHD medication treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4088/jcp.19r13015

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 40

  1. [6]Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36(2):159-165. PubMed CrossRef
  2. [8]Dalsgaard S, טstergaard SD, Leckman JF, et al. Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet. 2015;385(9983):2190-2196. PubMed CrossRef
  3. [9]Faraone SV, Asherson P, Banaschewski T, et al. Attention-deficit/hyperactivity disorder. Nat Rev Dis Primers. 2015;1(1):15020. PubMed CrossRef
  4. [10]Able SL, Johnston JA, Adler LA, et al. Functional and psychosocial impairment in adults with undiagnosed ADHD. Psychol Med. 2007;37(1):97-107. PubMed CrossRef
  5. [13]Epstein JN, Weiss MD. Assessing treatment outcomes in attention-deficit/hyperactivity disorder: a narrative review. Prim Care Companion CNS Disord. 2012;14(6):11r01336. PubMed
  6. [14]Coghill DR, Banaschewski T, Soutullo C, et al. Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry. 2017;26(11):1283-1307. PubMed CrossRef
  7. [15]Kooij JJS, Bijlenga D, Salerno L, et al. Updated European Consensus Statement on diagnosis and treatment of adult ADHD. Eur Psychiatry. 2019;56(1):14-34. PubMed CrossRef
  8. [16]Bolea-Alama×±ac B, Nutt DJ, Adamou M, et al; British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(3):179-203. PubMed CrossRef
  9. [17]Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894-921. PubMed CrossRef
  10. [18]Wolraich M, Brown L, Brown RT, et al; Subcommittee on Attention-Deficit/Hyperactivity Disorder; Steering Committee on Quality Improvement and Management. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128(5):1007-1022. PubMed CrossRef
  11. [19]Joseph A, Ayyagari R, Xie M, et al. Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison. Eur Child Adolesc Psychiatry. 2017;26(8):875-897. PubMed CrossRef
  12. [20]Padilha SCOS, Virtuoso S, Tonin FS, et al. Efficacy and safety of drugs for attention deficit hyperactivity disorder in children and adolescents: a network meta-analysis. Eur Child Adolesc Psychiatry. 2018;27(10):1335-1345. PubMed CrossRef
  13. [21]Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727-738. PubMed CrossRef
  14. [22]Yoshida M, Obara T, Kikuchi S, et al. Drug prescriptions for children with ADHD in Japan: a study based on health insurance claims data between 2005 and 2015. J Atten Disord. 2020;24(2):175-191. PubMed CrossRef
  15. [23]Hales CM, Kit BK, Gu Q, et al. Trends in prescription medication use among children and adolescents—United States, 1999-2014. JAMA. 2018;319(19):2009-2020. PubMed CrossRef
  16. [24]Renoux C, Shin JY, Dell’ Aniello S, et al. Prescribing trends of attention-deficit hyperactivity disorder (ADHD) medications in UK primary care, 1995-2015. Br J Clin Pharmacol. 2016;82(3):858-868. PubMed CrossRef
  17. [25]McCarthy S, Asherson P, Coghill D, et al. Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults. Br J Psychiatry. 2009;194(3):273-277. PubMed CrossRef
  18. [26]Wehmeier PM, Schacht A, Dittmann RW, et al. Effect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double-blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder. Qual Life Res. 2011;20(5):691-702. PubMed CrossRef
  19. [27]Ingram S, Hechtman L, Morgenstern G. Outcome issues in ADHD: adolescent and adult long-term outcome. Ment Retard Dev Disabil Res Rev. 1999;5(3):243-250. CrossRef
  20. [28]MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics. 2004;113(4):762-769. PubMed CrossRef
  21. [29]MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics. 2004;113(4):754-761. PubMed CrossRef
  22. [30]van de Loo-Neus GH, Rommelse N, Buitelaar JK. To stop or not to stop? how long should medication treatment of attention-deficit hyperactivity disorder be extended? Eur Neuropsychopharmacol. 2011;21(8):584-599. PubMed CrossRef
  23. [31]Buitelaar J, Asherson P, Soutullo C, et al. Differences in maintenance of response upon discontinuation across medication treatments in attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol. 2015;25(10):1611-1621. PubMed CrossRef
  24. [32]Coghill D, Danckaerts M, Sonuga-Barke E, et al; ADHD European Guidelines Group. Practitioner review: quality of life in child mental health—conceptual challenges and practical choices. J Child Psychol Psychiatry. 2009;50(5):544-561. PubMed CrossRef
  25. [33]WHOQOL. The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med. 1995;41(10):1403-1409. PubMed CrossRef
  26. [34]Ahnemark E, Di Schiena M, Fredman AC, et al. Health-related quality of life and burden of illness in adults with newly diagnosed attention-deficit/hyperactivity disorder in Sweden. BMC Psychiatry. 2018;18(1):223. PubMed CrossRef
  27. [35]Wong ICK, Banaschewski T, Buitelaar J, et al; European ADHD Guidelines Group. Emerging challenges in pharmacotherapy research on attention-deficit hyperactivity disorder-outcome measures beyond symptom control and clinical trials. Lancet Psychiatry. 2019;6(6):528-537. PubMed CrossRef
  28. [36]Moher D, Liberati A, Tetzlaff J, et al; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. PubMed CrossRef
  29. [39]Buitelaar JK, Michelson D, Danckaerts M, et al. A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year. Biol Psychiatry. 2007;61(5):694-699. PubMed CrossRef
  30. [40]Coghill DR, Banaschewski T, Lecendreux M, et al. Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design. J Am Acad Child Adolesc Psychiatry. 2014;53(6):647-657.e1. PubMed CrossRef
  31. [41]Michelson D, Buitelaar JK, Danckaerts M, et al. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry. 2004;43(7):896-904. PubMed CrossRef
  32. [42]Newcorn JH, Harpin V, Huss M, et al. Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study. J Child Psychol Psychiatry. 2016;57(6):717-728. PubMed CrossRef
  33. [43]Biederman J, Mick E, Surman C, et al. A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2010;30(5):549-553. PubMed CrossRef
  34. [44]Brams M, Weisler R, Findling RL, et al. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design. J Clin Psychiatry. 2012;73(7):977-983. PubMed CrossRef
  35. [45]Buitelaar JK, Trott GE, Hofecker M, et al. Long-term efficacy and safety outcomes with OROS-MPH in adults with ADHD. Int J Neuropsychopharmacol. 2012;15(1):1-13. PubMed CrossRef
  36. [47]Schwartz CE, Rapkin BD. Reconsidering the psychometrics of quality of life assessment in light of response shift and appraisal. Health Qual Life Outcomes. 2004;2(1):16. PubMed CrossRef
  37. [49]Osland S, Hirsch L, Pringsheim T. Smoking, alcohol and drug use in youth and adults with attention-deficit hyperactivity disorder. BJPsych Open. 2017;3(3):141-146. PubMed CrossRef
  38. [50]McCabe SE, Dickinson K, West BT, et al. Age of onset, duration, and type of medication therapy for attention-deficit/hyperactivity disorder and substance use during adolescence: a multi-cohort national study. J Am Acad Child Adolesc Psychiatry. 2016;55(6):479-486. PubMed CrossRef
  39. [51]Fredriksen M, Halm׸y A, Faraone SV, et al. Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: a review of controlled and naturalistic studies. Eur Neuropsychopharmacol. 2013;23(6):508-527. PubMed CrossRef
  40. Privacy Policy Terms of Use Physicians Postgraduate Press, Inc. JCP ISSN: Online 1555-2101, Print 0160-6689 PCC ISSN: Online 2155-7780, Print 2155-7772 MedFair.com US Patent No. 684794 © Copyright 2026 | Physicians Postgraduate Press, Inc. | LifeLong Learning For Clinicians Sitemap

Cited by

See all 31

Metadata

Authors
Tsujii, N., Okada, T., Usami, M., Kuwabara, H., Fujita, J., Negoro, H., Kawamura, M., Iida, J., & Saito, T.
Affiliations
  • Kindai University (JP)
  • Nagoya University (JP)
  • Kohnodai Hospital, National Center for Global Health and Medicine (JP)
  • Yokohama City University Hospital (JP)
  • Nara University of Education (JP)
  • Hokkaido University (JP)
  • Nara Medical University (JP)
Corresponding author
Okada, Takashi
Venue
The Journal of Clinical Psychiatry
Published
2020-03-24
Volume
81
Issue
3
ISSN
  • 0160-6689 (ISSN-L)
  • 1555-2101
OpenAlex
W3013248890
Cited by
31
References
6
Citations by year
2026: 4 · 2025: 3 · 2024: 7 · 2023: 5 · 2022: 8 · 2021: 2 · 2020: 2
FWCI
0.71
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Hokkaido University
  • Japan Society for the Promotion of Science (19K08044, 17K10339, 16K10248)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
Keywords
attention deficit hyperactivity disorder, quality of life, symptom remission, drug withdrawal, children and adolescents, adult ADHD, pharmacotherapy
MeSH terms
Adolescent, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Child, Humans, Quality of Life, Remission Induction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Continuing and Discontinuing Medications on Quality of Life After Symptomatic Remission in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis. https://app.cochat.ai/papers/10.4088/jcp.19r13015
The paper
Tsujii, N., Okada, T., Usami, M., Kuwabara, H., Fujita, J., Negoro, H., Kawamura, M., Iida, J., & Saito, T. (2020). Effect of Continuing and Discontinuing Medications on Quality of Life After Symptomatic Remission in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.19r13015

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.